← Leaderboards
Haobin Chen
Division Of Basic Sciences - Nci
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Division Of Basic Sciences - Nci
Same institution · by research overlap
Others in their field
Top investigators on “Cancer Cell Line”
- David Heimbrook · Leidos Biomedical Research, Inc.$181,009,042
- Larry Arthur$41,510,805
- Steven A Belinsky · Lovelace Biomedical &Environmental Res$26,419,484
- David H Haussler · University Of California Santa Cruz$25,140,916
- William C Hahn · Dana-Farber Cancer Institute$24,401,088
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$24,172,074
Research focus
Cancer Cell LineLung Small Cell CarcinomaBromodomainMouse ModelInhibitor/AntagonistPharmaceutical PreparationsResistanceTranscriptomeCollaborationsCancer PatientXenograft ProcedurePredictive MarkerMalignant NeoplasmsScreeningIn VitroBiological MarkersPatient SubsetsClinicMalignant Neoplasm Of LungDrug CombinationsGenetic SignatureGene Expression ProfileGenesDrug Synergism
Grant awards (11)
Developing an Effective BET bromodomain inhibitor Drug Combo to Target SCLC$243,898
ZIA · FY2022 · CA · contact PI
Predictive biomarker of BET bromodomain inhibitor in Small cell lung cancer$243,898
ZIA · FY2022 · CA · contact PI
Predictive biomarker of BET bromodomain inhibitor in Small cell lung cancer$436,781
ZIA · FY2021 · CA · contact PI
Developing an Effective BET bromodomain inhibitor Drug Combo to Target SCLC$436,781
ZIA · FY2021 · CA · contact PI
Predictive biomarker of BET bromodomain inhibitor in Small cell lung cancer$572,509
ZIA · FY2020 · CA · contact PI
Developing an Effective BET bromodomain inhibitor Drug Combo to Target SCLC$572,509
ZIA · FY2020 · CA · contact PI
Developing an Effective BET bromodomain inhibitor Drug Combo to Target SCLC$451,422
ZIA · FY2019 · CA · contact PI
Predictive biomarker of BET bromodomain inhibitor in Small cell lung cancer$451,422
ZIA · FY2019 · CA · contact PI
Predictive biomarker of BET bromodomain inhibitor in Small cell lung cancer$387,908
ZIA · FY2018 · CA · contact PI
Developing an Effective BET bromodomain inhibitor Drug Combo to Target SCLC$96,977
ZIA · FY2018 · CA · contact PI
Predictive biomarker of BET bromodomain inhibitor in Small cell lung cancer$341,450
ZIA · FY2017 · CA · contact PI